Primary Photoelectric Properties of Powder ACEL Soft Plastic Lamps

粉末交流电致发光（ACEl）塑料软屏是交流电致发光器件中的后起之秀，它有许多优越的物理特性，具有重要的实用价值。本文对这种发光屏的结构以及它的主要光电性能作了较详细的介绍。Powder ACEL soft plastic lamps,which have many superior physical properties and important practical values,are promising devices in ELField.In this paper,the structure and the photoelectric properties of the lamps are introduced in detail.国家和福建省自然科学基

EFFECT of MEDIUMS ON AGEING PERPORMENCE of AC POWDER ELECTROLUMINESCENT DEVICE

本文研究了介质对交流粉末电致发光器件的发光老化性的影响，用具有特殊性能的水溶性苯丙乳胶作为介质制备的交流粉末电致发光器件，其发光老化性能得到较大幅度提高；并分析了这种发光器件老化的主要原因和机制，提出防止发光老化应注意的问题。The eFFect of the mediums on agening perFormence of AC powder electroluminescent deviCe is tesearched,the special water-soluble phenylpropioniC emulsion used as a medium is introduced into AC powder electroluminescent davids and the ageing perFormence of the device is raised.The main cause and mechanism For the ageing of,lectroluminescent device is analoged and the problems on avoidins ageing is also given as well.国家自然科学基

粉末电致发光的新应用──一种光神经器件

近年来，人工神经网格与神经网络计算机的研究在世界范围内已形成一个热点，本文通过对电致发光材料的各种特性的讨论，分析了固体化平板电致发光作为一种光神经器件的一些特点，指出了它在神经网络实现中有很好的应用前景

Methods of Measuring Luminous Lives For Powder ACEL Devices

粉末ACEl器件发光寿命的测试方法1胡启富（厦门大学物理学系厦门361005）目前测量粉末ACEl器件的发光寿命主要有三种方法：1）常规测试法；2）类比法；3）拟合公式和双对数坐标法.究竟哪一种方法能较准确、快速测出这种器件的发光寿命？这是从事粉末A...The author analyses and discusses the three existing methods of measuring luminous lives For powder ACEL devices and then points out their advantages and disadvantages by giving the concrete results of experiments.国家自然科学基

Preparation and Structure Analysis of Zinc SulFide Thin Film

用常规分舟热蒸发法在玻璃衬底上制备硫化锌薄膜，用X射线衍射和透射电子显微镜研究该薄膜的晶体结构，发现硫化锌薄膜与流化锌粉末在晶体结构上存在差异，实验证实硫化锌晶体是具有高于性的共价键晶体。The zinc sulFide thin Films have been prepared on glass substrate by thermal evaporation with two separate boats in vacuum.AFter studing the Films with X-ray diFFraction (XRD) and transmission electron microscope (TEM), structures of the Film and the powder of ZnS are Found to be diFFerent.The experimental results indicate that the crystalline of the zinc sulFide is the one of covalent bond with ionicity.福建省自然科学基

横向场电离室在RIBLL实验中的应用

描述一种可用于兰州放射性束流线(RIBLL)上的ΔE探测器——横向场气体电离室．对其性能进行了测试,包括它的坪曲线、探测效率和能量分辨．测试结果显示,在混合气Ar(80％)+CO2(20％)的不同气压下,此电离室具有较长的工作坪区,较小的坪斜．相对于Si的探测效率为99．31％．在118mbar的气压下,对能损为4．94MeV的α粒子,其能量分辨率为3．25％．并在RIBLL上利用50MeV／u的58Ni轰击Ta靶的实验中进行了在束应用

~(17)B的晕结构特征

实验利用束流衰减法测量了43.7AMeV丰中子核17B与C靶反应的总截面σR=(1724±93)mb.用零程Glauber计算,假定17B具有核芯15B和两个价中子结构,输入GG和GO密度分布,计算的激发函数曲线与该实验数据很好符合,输入描述稳定核双参数Fermi密度分布,不能得到与实验数据符合的结果,表明17B是核芯15B+2n的假定是合理的.并且中子密度分布表现较大空间扩展-晕结构特征

激发态~(17)Ne双质子2p发射的实验

<正>在中国科学院近代物理研究所放射性束流装置RIBLL上完成了17Ne+197Au的实验,采用硅条探测器与CsI(Tl)+PIN探测器阵列进行运动学完全测量,研究了17Ne双质子发射的机制。实验选

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials